Takayasu's arteritis (TA) is a rare large-vessel vasculitis that affects large arteries, mainly the aorta and its branches. It is also called a pulseless disease because of diminished or absent pulses in the upper extremities of the patient. The coronary, pulmonary and renal arteries are also affected in the progression of the disease. The prevalence of the disease is more in Asian countries and it has unknown etiopathogenesis. Here we discuss a case of TA in a 15 y old girl who was admitted with moderate LV dysfunction. The diagnosis was carried out from the results of CT aortogram which showed stenosis of right common carotid, left subclavian, left vertebral artery, right renal artery and lower lobe pulmonary arteries and other clinical examinations. Treatment was initiated with methylprednisolone and cyclophosphamide along with symptomatic treatment. But the disease progressed with the development of complications like peripheral leg ulcers. The patient was initiated palliative care in view of altered sensorium and severe LV dysfunction, but the patient succumbed to a sudden cardiac arrest. Early identification and initiation of aggressive treatment can help in symptom-free survival.
Background: For post Percutaneous Transluminal Coronary Angioplasty for Acute Coronary Syndromes, Dual Antiplatelet Therapy with Aspirin and a P2Y12 receptor inhibitor like Ticagrelor or Clopidogrel is required minimum for a period of 12 months. There are few studies which have shown the incidence of dyspnea in patients receiving antiplatelet therapy. Methods: In this retrospective, single centre, cohort study, patients who underwent PTCA and were on dual antiplatelets were randomly selected from the clopidogrel and ticagrelor group between July 2013 and June 2014. Patient's relevant data were collected from electronic medical records and cross checked with manually maintained medical records wherever necessary. The study endpoint was incidence of dyspnoea within a follow up period of 9 months. Results: Among the 100 patients started on dual antiplatelet therapy with aspirin and ticagrelor, dyspnea occurred in 10% patients. Ticagrelor was substituted with clopidogrel in 60% cases. In 100 patients on clopidogrel, dyspnea occurred in 5% of patients, but clopidogrel was continued in all cases. Onset of dyspnea in patients on Ticagrelor occurred in 50% of patients in the first month of follow up, 10% cases at 3 months, 30% cases at 6 months and 10% cases at 9 months. But in clopidogrel group dyspnea occurred in 40% cases at 6 months follow up and 60% cases at 9 months. The p value on comparison of dyspnoea among the two groups was found to be 0.283, which was not statistically significant probably due to less sample population. Conclusion: Risk for dyspnoea induced by Ticagrelor was found to be higher than with Clopidogrel in the same ethnic groups when used as dual antiplatelet along with Aspirin. So it may not be a class effect or due to P2Y12 receptor inhibitory action alone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.